Clinical trial
Effect of the Antidiabetic Drug DAPAgliflozin on the Coronary Macrovascular and MICROvascular Function in Type 2 Diabetic Patients
NCT05392959 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire Saint Pierre as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of the Antidiabetic Drug DAPAgliflozin on the Coronary Macrovascular and MICROvascular Function in Type 2 Diabetic Patients
- Lead sponsor
- Centre Hospitalier Universitaire Saint Pierre
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- June 6, 2022
- Completion date
- July 17, 2023
- Enrollment
- 4 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.